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for Clonazepam and 181 for Fluoxetine and Imipramine. The
incremental cost-effectiveness analysis showed that the cost of an
extra unit of effectiveness was $32.2 when changing from Alpra-
zolam to Clonazepam, while the two other alternatives (Fluox-
etine and Imipramine) were dominated. Sensitivity analysis
conﬁrmed the direction and strength of our results. Conﬁdence
interval at 95% of the ICER was calculated by the ellipse method
and it showed that Alprazolam was dominant in 87% of the
cases. Acceptability curve described Alprazolam as the best
option with a willingness to pay threshold of $32.2. CONCLU-
SIONS: The best cost-effective alternative was Alprazolam fol-
lowed by Clonazepam. This results are relevant for the IMSS
because anxiety disorders cause work leaves and hospitalisa-
tions, and reduction in quality of life.
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OBJECTIVES: To assess the health and cost burdens of patients
with generalized anxiety disorder (GAD) and other anxiety dis-
orders, including their comorbidities, direct and indirect costs.
METHODS: The 1999–2003 MarketScan® claims databases of
over three million individuals (annually) were used to identify
patients with a diagnosis of GAD, other anxiety disorders (panic
disorder, phobias, post traumatic stress disorder, unspeciﬁed
anxiety state), and demographically-matched controls. Presence
of comorbidities, utilization, expenditures, absence and short-
term disability (STD) were summarized over a 12-month study
period. RESULTS: The prevalence of the following conditions
were signiﬁcantly (p < 0.001) higher among the 13,836 GAD
subjects and 31,882 other anxiety patients compared to the
89,971 controls: gastrointestinal disorders (19% GAD, 22%
other anxiety, 12% controls), genitourinary disorders (40%
GAD and other anxiety, 32% controls), cardiovascular disease
(10% GAD, 11% other anxiety, 7% controls), and chronic pain
(40% GAD, 44% other anxiety, 20% controls). Mean costs for
anxiety patients were twice as high as for controls ($6295 GAD,
$6800 other anxiety, $3156 controls, p < 0.001). These differ-
ences were driven by signiﬁcantly higher rates of ofﬁce visits and
prescription drug use among anxiety patients. Mental health
costs for GAD patients ($2031) or other anxiety patients ($2005)
did not account for all of the discrepancy. Among the subset of
patients with productivity data, anxiety patients had signiﬁcantly
higher indirect costs due to STD days ($2253 GAD, $3255 other
anxiety, $934 controls, p < 0.001). CONCLUSION: Patients
with GAD and other anxiety disorders have signiﬁcantly higher
costs compared to patients without these conditions. The direct
and indirect costs of anxiety result from mental health treatment
and treatments for physical comorbidities.
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OBJECTIVES: To examine the determinants of time-to-
permanent nursing home admission among people aged 65 years
and over in the United States. METHODS: This study used data
from four waves of the Health Retirement Study (HRS) and
Assets and Health Dynamics among the Oldest Old surveys
(AHEAD) collected from 1995 to 2002. The dependent variable
was time-to-permanent nursing home admission, deﬁned as the
months from baseline survey in 1995 to the ﬁrst nursing home
stay of three or more months. Independent variables were mea-
sured at the baseline and included age, gender, race, education,
marital status, living arrangements, income, homeownership,
Medicaid, physical function (ADL/IADL), cognitive level, per-
ceived health status and certain chronic illnesses such as stroke,
psychiatric problems, fall and incontinence. RESULTS: In the
ﬁnal multivariable Cox model, older age (Hazard Ratio [HR],
1.11; 95% CI, 1.09–1.24), persons with psychiatric problems
(HR, 1.49; 95% CI, 1.19–1.87) and worse health were found 
to increase the risk of permanent nursing home admission
whereas being African American compared to white (HR, 0.85;
95% CI, 0.56–0.95) and persons with less cognitive impairment
(HR, 0.95; 95% CI, 0.91–0.99) had decreased risk. The inter-
action terms between time and living alone and IADL were 
signiﬁcant and less than one, which means the negative impacts
of living alone and worse IADL were decreasing over time.
Gender, education, marital status, income, homeownership,
Medicaid, ADL, stroke, fall and incontinence were not signiﬁ-
cant. CONCLUSION: Older age, psychiatric problems and
worse perceived health are the risk factors for permanent nursing
home admission. Living alone and worse IADL also increase the
risk of nursing home admission, however, the negative impacts
appear to ameliorate over time. The differential effects of ADL
and IADL on nursing home admission warrant more future
research.
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OBJECTIVES: This study assessed the effect of treatment with
venlafaxine extended release (XR), paroxetine and placebo on
health related work productivity among panic disorder patients.
METHODS: In a multicenter, double-blind trial, patients with
DSM-IV panic disorder were randomly assigned to ﬁxed-dose
(75mg/day or 225mg/day) venlafaxine XR, paroxetine 
(40mg/day), or placebo for a maximum of 12-weeks. Secondary
analyses focused on health-related work productivity impair-
ments as measured by the Work Limitations Questionnaire
(WLQ). WLQ has 25 items in four limitation dimensions (time,
physical, mental-interpersonal, and output demands). Treat-
ment-related improvements at ﬁnal-on-therapy (FOT) and week
12 were compared using analysis of covariance adjusting for
baseline impairment score and center. RESULTS: Venlafaxine
XR 225mg was associated with signiﬁcantly greater improve-
ment from baseline, relative to placebo, on all subscales of WLQ
(P < 0.005) except physical demands. At the FOT assessment,
venlafaxine XR 75mg showed signiﬁcant improvement com-
pared with placebo in time management (P < 0.05), marginally
signiﬁcant improvement in mental/interpersonal demands (P =
0.059) and output demands (P = 0.054), and no signiﬁcance 
for physical demands. Paroxetine failed to show signiﬁcant
improvement relative to placebo on all WLQ subscales in the
FOT assessment. CONCLUSION: Venlafaxine reduced work
impairment compared to placebo. Paroxetine did not separate
from placebo.
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OBJECTIVES: Attention-deﬁcit hyperactivity disorder (ADHD)
is a common disorder that is associated with broad functional
impairment among both children and adults. The purpose of this
project was to review literature on the economic costs of ADHD,
as well as potential economic beneﬁts of treating this condition.
METHODS: A literature search was performed using MEDLINE
to identify all published articles on the economic implications 
of ADHD, and authors were contacted to locate conference
abstracts and articles in press that were not yet indexed. In total,
22 relevant items were located including published original
studies, economic review articles, conference presentations, and
reports available on the Internet. RESULTS: Results of medical
cost studies consistently indicated that children with ADHD had
higher annual medical costs than either matched controls 
(difference ranged from $503 to $1343) or non-matched con-
trols (difference ranged from $207 to $1560) without ADHD.
Two studies of adult samples found similar results. A limited
number of studies have examined other economic implications
of ADHD including costs to families; costs of criminality among
individuals with ADHD; costs related to common psychiatric
and medical comorbidities of ADHD; and costs of accidents
among individuals with ADHD. Treatment cost-effectiveness
studies have primarily focused on methylphenidate, which is a
cost-effective treatment option with cost-effectiveness ratios
ranging from $15,509 to $27,766 per quality-adjusted life year
(QALY) gained. CONCLUSIONS: A growing body of literature,
primarily published in the United States, has demonstrated that
ADHD places a substantial economic burden on patients, fami-
lies, and third-party payers. Recognition, diagnosis and treat-
ment of ADHD are increasing in Europe and Australia, and
future studies may document the economic burden of ADHD in
these areas. As new treatments are introduced, it will be impor-
tant to evaluate their cost-effectiveness to provide an indication
of their potential value.
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OBJECTIVES: To develop a tool to allow estimation of the
budget impact of treatments for acute mania in bipolar I disor-
der from a US health care payer perspective. METHODS: Course
of each individual is simulated beginning with hospitalization.
Discharge depends on the level of symptoms as measured by the
Young Mania Rating Scale (YMRS). The effect of treatment is
determined using time-dependent regression equations derived
from trial data, and decision rules obtained from clinical experts.
Outcomes include: time to response and symptom resolution;
proportion of subjects reaching each outcome; number of
adverse events. Medical care costs were obtained from hospital
discharge databases, the National Medicare Physician Fee Sched-
ule and RedBook. Different scenarios are examined, each
describing the proportion of subjects on the various treatments
(lithium; divalproex sodium; olanzapine, risperidone and queti-
apine—monotherapy and in combination with lithium). The
base case scenario was derived from the distribution of treat-
ments observed in a state Medicaid population. Subjects may
switch treatment at any point, but analyses are intention-to-treat
over 100 days, corresponding to follow-up in mania trials.
RESULTS: Scenarios with a greater proportion of quetiapine
users (5% vs. 40% and 100%) result in a smaller impact on the
health care budget ($6912, $6277 and $5525 per patient, respec-
tively) and improvements in patient outcomes (e.g., 43%, 47%
and 54% responding at day 21; 74%, 77% and 80% remitting
by day 84). Quetiapine is cost-saving compared to olanzapine
(about $250 per patient), mainly due to fewer side-effects. Sen-
sitivity analyses showed the budget impact is inﬂuenced by drug
prices, discharge criteria and side-effect management. CON-
CLUSIONS: Results suggest that increased use of quetiapine for
mania in the US is economically sound and will improve health
outcomes. In addition, this model illustrates that discrete event
simulation is a very useful and versatile tool for budget impact
analyses.
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OBJECTIVE: To compare mental health-related costs among
patients with bipolar disorder treated with atypical antipsy-
chotics in a managed care setting. METHODS: This was a ret-
rospective cohort study using administrative claims data from a
national managed care organization. Participants initiated treat-
ment with risperidone, olanzapine, or quetiapine between July
1, 2000 and December 31, 2002, and had a bipolar disorder
diagnosis within six months of the index prescription for an
atypical antipsychotic. Subjects treated with more than one
antipsychotic at index were excluded. Subjects were matched one
to one on the propensity to receive risperidone using a score esti-
mated from a logistic regression model, which included age,
gender, psychiatric comorbidities, plan type, geographic region
and mood stabilizer use. Once matched, 12 months of follow-
up mental health-related costs and utilization data were com-
pared using univariate statistics. RESULTS: The olanzapine
cohort accounted for half of the study patients (n = 1660, 50%)
followed by the risperidone (n = 951, 29%) and quetiapine
cohorts (n = 699, 21%). After adjusting for treatment selection
bias through propensity matching, risperidone- and olanzapine-
treated subjects had similar mental health costs ($5728 vs.
$5908, respectively, NS). The cost of psychotropic therapy was
signiﬁcantly higher for the olanzapine versus risperidone cohort
($3363 vs. $2969, p = 0.001) and was the only signiﬁcant dif-
ference between these cohorts. Risperidone patients had signiﬁ-
cantly lower mental health costs compared to subjects treated
with quetiapine ($5666 vs. $6579, respectively, p = 0.007). Sub-
jects treated with risperidone also had signiﬁcantly lower psy-
chotropic therapy costs compared to quetiapine subjects ($2929
vs. $3492 respectively, p < 0.0001). CONCLUSION: In a
managed care setting, patients with bipolar disorder treated with
risperidone had similar mental health costs compared to patients
receiving olanzapine, and lower mental health costs compared to
those treated with quetiapine. This study provides important
comparative information on the real world cost of bipolar
patients treated with atypical antipsychotics.
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